The GDPR (General Data Protection Regulation) includes provisions that support the secondary use of existing health data for scientific research purposes, while also protecting the privacy and data protection rights of individuals.
One of the key ways that the GDPR supports the secondary use of health data for research is through the concept of “legitimate interests”. Article 6(1)(f) of the GDPR allows for the processing of personal data if it is necessary for the legitimate interests of the data controller or a third party, provided that those interests do not override the fundamental rights and freedoms of the data subject. Scientific research can be considered a legitimate interest, provided that appropriate safeguards are in place to protect individuals’ rights and freedoms.
In addition, the GDPR includes provisions that specifically address the use of health data for scientific research. For example, Article 9(2)(j) allows for the processing of special categories of personal data, such as health data, for scientific research purposes, provided that appropriate safeguards are in place.
The GDPR also requires that data controllers implement appropriate technical and organizational measures to ensure the security and confidentiality of personal data, including health data. This includes requirements for data pseudonymization and encryption, as well as procedures for data breach notification.
Overall, the GDPR strikes a balance between protecting individuals’ privacy and data protection rights, and supporting the important public interest in scientific research. By providing a framework for the responsible and transparent use of health data for research purposes, the GDPR can help to facilitate the development of new treatments and interventions that can improve public health outcomes.
Share this story...
Real World Evidence (RWE) – TMF Reference Model versus the Real-World Study Document Index (RWS-DI)
RWE 101 - TMF Reference Model versus the Real-World Study Document Index (RWS-DI) The Real World Study-Document Index (RWS-DI) is a framework developed by a working group of RWE [...]
Real World Evidence (RWE) 101 – ISF vs TMF
RWE 101 - ISF vs TMF Investigator Site File (ISF) and Trial (Study) Master File (TMF) are key elements in managing clinical and observational studies. They are distinct but [...]
Real World Evidence (RWE) 101 – Study Conduct
RWE 101 - Study Conduct Once the study has been set up, the study conduct phase begins. This phase includes several key activities that ensure the smooth running of [...]
Real World Evidence (RWE) 101 – Monitoring
RWE 101 - Monitoring Monitoring requirements for Real-World Evidence (RWE) studies may differ from those of traditional randomized controlled trials due to the nature of data collection and the [...]
Real World Evidence (RWE) 101 – eConsent
RWE 101 - eConsent Electronic consent or eConsent refers to the process of using electronic systems and processes to convey information related to the study and to obtain and [...]
Real World Evidence (RWE) 101 – Consent to Participate in Research vs Consent to Access and Process Sensitive Healthcare Data (GDPR)
RWE 101 - Consent to Participate in Research vs Consent to Access and Process Sensitive Healthcare Data (GDPR) Consent to participate in research and consent to access and process [...]







